Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18932078 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18928880 | CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18819737 | RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use | August 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18765286 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18741110 | ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNA | June 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18739091 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18646631 | APTAMERS FOR BINDING TO A MEMBRANE-BASED LIPID | April 2024 | December 2024 | Allow | 8 | 1 | 1 | No | No |
| 18435472 | APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAME | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18470687 | CFTR-MODULATING COMPOSITIONS AND METHODS | September 2023 | November 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 17720996 | FN3 Domain-siRNA Conjugates and Uses Thereof | April 2022 | November 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17671688 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | February 2022 | November 2023 | Abandon | 21 | 2 | 1 | No | No |
| 17590754 | ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION | February 2022 | September 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17547879 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | December 2021 | March 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17542046 | T-LYMPHOCYTE BINDING APTAMERS | December 2021 | July 2024 | Allow | 31 | 2 | 1 | No | No |
| 17542055 | POLYMER NANOPARTICLE AND DNA NANOSTRUCTURE COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY | December 2021 | June 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17540569 | Antisense Oligonucleotides Targeting ATXN3 | December 2021 | January 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17535070 | SINGLE-NUCLEI CHARACTERIZATION OF AMYOTROPHIC LATERAL SCLEROSIS FRONTAL CORTEX | November 2021 | October 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17456239 | DUAL FUNCTIONAL EXPRESSION VECTORS AND METHODS OF USE THEREOF | November 2021 | September 2023 | Abandon | 22 | 1 | 1 | No | No |
| 17455528 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | November 2021 | November 2024 | Abandon | 36 | 3 | 1 | Yes | No |
| 17528851 | mRNA NANOCAPSULE AND USE IN PREPARATION OF ANTIVIRAL DRUGS | November 2021 | March 2024 | Abandon | 28 | 1 | 1 | Yes | No |
| 17524586 | NOVEL RNA TRANSCRIPT | November 2021 | June 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17522418 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | November 2021 | September 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17451428 | COMPOSITIONS AND METHODS FOR MODULATING MYC TARGET PROTEIN 1 | October 2021 | December 2024 | Allow | 38 | 3 | 0 | Yes | No |
| 17598150 | Inhibition of Monoamine Oxidase Subtype A (MAOA) Mitigates Cardiovascular Calcification | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17398252 | METHODS FOR DETERMINING INCREASED RISK OF CANCER DEVELOPMENT AND TREATING THE SAME | August 2021 | November 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17365777 | SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS | July 2021 | January 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17417718 | TREATMENT OF SPINAL CONDITIONS WITH CHIMERA DECOY | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17415262 | MIRNA FOR USE IN THERAPY | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17303051 | dsRNA Directed to Coronavirus Proteins | May 2021 | April 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17319291 | MESSENGER RNA ENCODING CAS9 FOR USE IN GENOME-EDITING SYSTEMS | May 2021 | August 2024 | Allow | 39 | 3 | 1 | No | No |
| 17285569 | Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) | April 2021 | February 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17231588 | CONTROL OF REPLICATION AND TRANSCRIPTION OF SELF-REPLICATING RNA IN RESPONSE TO SMALL MOLECULES | April 2021 | July 2024 | Allow | 39 | 3 | 0 | Yes | No |
| 17282502 | METHOD FOR TREATING RETINAL DEGENERATION DISEASE BY ADMINISTERING NUCLEOLIN POLYNUCLEOTIDE OR POLYPEPTIDE | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17213787 | RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use | March 2021 | May 2024 | Allow | 38 | 4 | 0 | Yes | No |
| 16969314 | APTAMER FOR SCLEROSTIN AND USE THEREOF | March 2021 | February 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17187018 | COMPOUNDS AND METHODS FOR MODULATING SMN2 | February 2021 | May 2025 | Abandon | 51 | 4 | 0 | Yes | No |
| 17271401 | POLYNUCLEOTIDES ENCODING VERY LONG-CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | February 2021 | December 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17266275 | SYSTEMS AND METHODS FOR APTAMER-BASED INTRACELLULAR DELIVERY OF A PAYLOAD USING NANONEEDLES | February 2021 | April 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17266069 | MICRORNA-BASED THERAPY TARGETED AGAINST LCP-1 POSITIVE CANCERS | February 2021 | June 2024 | Allow | 41 | 3 | 1 | Yes | No |
| 17163761 | NUCLEIC ACID APTAMERS | February 2021 | March 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17262052 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | January 2021 | November 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17261653 | SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE | January 2021 | September 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17253760 | COMPOSITION COMPRISING ANTISENSE OLIGONUCLEOTIDE AND USE THEREOF FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | December 2020 | January 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17058989 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | November 2020 | January 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17104562 | SINGLE BASE EDITING TOOLS WITH PRECISE ACCURACY | November 2020 | January 2025 | Abandon | 50 | 2 | 1 | No | No |
| 16951161 | COMPOSITIONS AND METHODS FOR INHIBITING THE PRODUCTION OR ACTIVITY OF D-2HYDROXYGLUTARATE IN SUBJECTS AFFLICTED WITH CANCER | November 2020 | September 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17098571 | SYSTEMS, METHODS, AND COMPOUNDS FOR PROVIDING CHAPERONE ACTIVITY TO PROTEINS | November 2020 | May 2023 | Allow | 30 | 1 | 1 | No | No |
| 17055378 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | November 2020 | January 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17093225 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC AND METABOLIC DISEASES | November 2020 | May 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17038704 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | September 2020 | November 2023 | Abandon | 37 | 1 | 0 | No | No |
| 17040796 | GUIDE RNA FOR HSV-1 GENE EDITING AND METHOD THEREOF | September 2020 | March 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17040629 | CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome | September 2020 | February 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16982733 | MODULATION OF HSD17B13 EXPRESSION | September 2020 | January 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17022678 | BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY | September 2020 | March 2025 | Allow | 54 | 3 | 1 | Yes | Yes |
| 16979892 | A DBAIT MOLECULE AGAINST ACQUIRED RESISTANCE IN THE TREATMENT OF CANCER | September 2020 | December 2024 | Abandon | 51 | 2 | 0 | No | No |
| 16970004 | MODIFIED VIRAL CAPSIDS | August 2020 | October 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16970193 | ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING | August 2020 | July 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16970090 | C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE | August 2020 | May 2024 | Abandon | 46 | 2 | 0 | No | Yes |
| 16754714 | METHODS AND COMPOSITIONS FOR EXPANSION OF CELL POPULATION | August 2020 | March 2025 | Allow | 59 | 1 | 2 | Yes | No |
| 16985779 | COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | August 2020 | January 2025 | Abandon | 53 | 2 | 1 | No | No |
| 15733306 | GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | June 2020 | May 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16954625 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | June 2020 | August 2024 | Abandon | 50 | 3 | 1 | No | No |
| 16763180 | MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY | May 2020 | October 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16647728 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | March 2020 | September 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16796439 | Optimized RPE65 Promoter and Coding Sequences | February 2020 | December 2023 | Allow | 46 | 1 | 0 | Yes | No |
| 16595924 | MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION | October 2019 | January 2023 | Abandon | 40 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARIETI, RUTH SOPHIA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ARIETI, RUTH SOPHIA works in Art Unit 1635 and has examined 58 patent applications in our dataset. With an allowance rate of 34.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner ARIETI, RUTH SOPHIA's allowance rate of 34.5% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ARIETI, RUTH SOPHIA receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ARIETI, RUTH SOPHIA is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +72.8% benefit to allowance rate for applications examined by ARIETI, RUTH SOPHIA. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.8% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 64.3% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 94.1% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.